Valion Bio, Inc. Undistributed Earnings (Loss) Available to Common Shareholders, Basic
Valion Bio, Inc. (VBIO) reported Undistributed Earnings (Loss) Available to Common Shareholders, Basic of -$7.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic · last filed 2026-08-14
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for the quarter ending 2026-06-30 was -$7.35M.
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for the quarter ending 2026-03-31 was -$6.44M.
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for the quarter ending 2025-12-31 was -$2.98M.
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for the quarter ending 2025-09-30 was -$2.64M.
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for fiscal 2025 was -$9.06M.
- Valion Bio, Inc. undistributed earnings (loss) available to common shareholders, basic for fiscal 2024 was -$5.66M.
| Period end | Undistributed Earnings (Loss) Available to Common Shareholders, Basic 3 month | Undistributed Earnings (Loss) Available to Common Shareholders, Basic 6 month | Undistributed Earnings (Loss) Available to Common Shareholders, Basic 9 month | Undistributed Earnings (Loss) Available to Common Shareholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.35M 10-Q · filed 2026-08-14 | -$13.79M 10-Q · filed 2026-08-14 | -$16.77M derived: sum of 3 quarters · filed 2026-08-14 | -$19.41M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$6.44M 10-Q · filed 2026-05-14 | -$9.42M derived: sum of 2 quarters · filed 2026-05-14 | -$12.06M derived: sum of 3 quarters · filed 2026-05-14 | -$13.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$5.62M derived: sum of 2 quarters · filed 2026-03-30 | -$7.55M derived: sum of 3 quarters · filed 2026-08-14 | -$9.06M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.64M 10-Q · filed 2025-11-14 | -$4.57M derived: sum of 2 quarters · filed 2026-08-14 | -$6.08M 10-Q · filed 2025-11-14 | -$7.55M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$1.93M 10-Q · filed 2026-08-14 | -$3.43M 10-Q · filed 2026-08-14 | -$4.91M derived: sum of 3 quarters · filed 2026-08-14 | -$6.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-14 | -$2.98M derived: sum of 2 quarters · filed 2026-05-14 | -$4.41M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$2.91M derived: sum of 2 quarters · filed 2026-03-30 | -$5.66M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$1.43M 10-Q · filed 2025-11-14 | -$4.18M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |